Histopathological and some biochemical effects of platinum drug on the liver and kidney of pregnant mice Mus musculus and their embryos
Iraqi Journal of Veterinary Sciences,
2021, Volume 35, Issue 2, Pages 291-300
10.33899/ijvs.2020.126793.1382
Abstract
The current study was done to investigate the effects of two doses 3and 6 mg/kg B.w. of the Platinum drug on the structure of the liver and kidney of pregnant mice, and embryos in addition to the weight of the mothers', embryos ,'maternal liver and kidneys, as well as some biochemical parameters, were established. For this study, thirty pregnant mice were used, divided into three groups (10 mice/group) as follows; group I (control group); animals were injected intraperitoneally (IP) with distilled water on the days 7th, 12th, and 17th of gestation. The other both groups II, and III were injected intraperitoneally (IP) with the selected doses above of the Platinum at the days 7th, 12th, and 17th of gestation, respectively. Microscopically, maternal and fetal' liver sections of group II revealed vacuolation, swelling, apoptosis, infiltration of inflammatory cells, congestion, degeneration, and presence of the extramedullary hematopoietic cells, respectively. Previous lesions were increased in group III. Maternal and, fetal kidney sections of group II revealed degeneration, expansion of Bowman's space, inflammatory cells infiltration into interstitial tissue, and blood capillaries congestion. However, the previous lesions showed more severity in group III. The drug caused a reduction in the body weight of the mothers, selected organs, and embryos. Biochemical assessment of the maternal serum AST, ALT, and ALP levels showed an increase in both experimental groups II and III, but to varying degrees. Moreover, both groups II and III showed an increase in the levels of the maternal BUN and, urea. Whist, group III showed a significant increase of the creatinine compared to the control group. In conclusion, using anticancer drugs during pregnancy will harm both mothers and fetal organs. The risk of these medications represents their ability to cross the placenta and enters the fetal body. Therefore, the drug may affect the formation of the fetal organs. The drug also alters the regulatory antioxidant mechanism in the maternal body during the treatment duration. The drug should be used under medical follow up.Histopathological and some biochemical effects of platinum drug on the liver and kidney of pregnant mice Mus musculus and their embryos
Baidaa Abdul-Aziz Mohammed Salah1 and Hanan Sadeq Sadoon2
Department of Biology, College of Education For Pure Science, University of Mosul, Mosul, Iraq
Baidaamohammed@uomosul.edu.iq (https://orcid.org/0000-0003-0570-072X)
Saadoon.hanan@gmail.com (https://orcid.org/0000-0003-3555-0451)
2020-03-12
2020-04-28
Abstract
The current study was done to investigate the effects of two doses 3and 6 mg/kg B.w. of the Platinum drug on the structure of the liver and kidney of pregnant mice, and embryos in addition to the weight of the mothers', embryos ,'maternal liver and kidneys, as well as some biochemical parameters, were established. For this study, thirty pregnant mice were used, divided into three groups (10 mice/group) as follows; group I (control group); animals were injected intraperitoneally (IP) with distilled water on the days 7th, 12th, and 17th of gestation. The other both groups II, and III were injected intraperitoneally (IP) with the selected doses above of the Platinum at the days 7th, 12th, and 17th of gestation, respectively. Microscopically, maternal and fetal' liver sections of group II revealed vacuolation, swelling, apoptosis, infiltration of inflammatory cells, congestion, degeneration, and presence of the extramedullary hematopoietic cells, respectively. Previous lesions were increased in group III. Maternal and, fetal kidney sections of group II revealed degeneration, expansion of Bowman's space, inflammatory cells infiltration into interstitial tissue, and blood capillaries congestion. However, the previous lesions showed more severity in group III. The drug caused a reduction in the body weight of the mothers, selected organs, and embryos. Biochemical assessment of the maternal serum AST, ALT, and ALP levels showed an increase in both experimental groups II and III, but to varying degrees. Moreover, both groups II and III showed an increase in the levels of the maternal BUN and, urea. Whist, group III showed a significant increase of the creatinine compared to the control group. In conclusion, using anticancer drugs during pregnancy will harm both mothers and fetal organs. The risk of these medications represents their ability to cross the placenta and enters the fetal body. Therefore, the drug may affect the formation of the fetal organs. The drug also alters the regulatory antioxidant mechanism in the maternal body during the treatment duration. The drug should be used under medical follow up.
Keywords: Platinum, Pregnancy, Fetuses , Liver, Kidney, Mice.
التغیرات النسجیة المرضیة وبعض التأثیرات الکیموحیویة لعقار البلاتینیوم على کبد وکلیة الفئران الحوامل Mus muscullusواجنتها
بیداء عبد العزیز محمد صالح و حنان صدیق سعدون
قسم علوم الحیاة، کلیة التربیة للعلوم الصرفة، قسم علوم الحیاة، کلیة التربیة للعلوم الصرفة، جامعة الموصل، الموصل، العراق
الخلاصة
اجریت الدراسة الحالیة للتحری عن تأثیر جرعتین هما 3 و 6 ملغم /کغم من وزن الجسم من عقار البلاتینیوم على ترکیب کل من کبد وکلیة الفئران الحوامل واجنتها و تسجیل التغیرات الوزنیة لکل من الأمهات الحوامل، الأجنة والأعضاء قید الدراسة، فضلا عن اجراء بعض الفحوص الکیموحیویة. استخدمت ثلاثون فأر حامل فی الدراسة الحالیة وقسمت الى ثلاث مجامیع (10 حیوانات /مجموعة) وکالاتی المجموعة الأولى (سیطرة) حقنت بالماء المقطر فی الخلب فی الأیام 7، 12، 17 من الحمل. المجموعتین الثانیة والثالثة فی الخلب بالجرعتین 3 و 6 ملغم /کغم من وزن الجسم من البلاتینیوم فی الأیام 7، 12، 17 من الحمل وعلى التوالی. مجهریا، أظهرت مقاطع الکبد للمجموعة الثانیة من الأمهات الحوامل تغیرات نسجیه تمثلت بالتفجی، احتقان، الموت المبرمج، ارتشاح الخلایا الالتهابیة، فی حین تمثلت الآفات فی کبد الجنین بالاحتقان وظهور الخلایا الدمویة الاولیة والتنکس وهذه الآفات ازدادت عند الترکیز 6ملغم /کغم من وزن الجسم فی کبد الامهات واجنتها. واظهرت مقاطع الکلیة للمجموعة الثانیة من الامهات الحوامل واجنتها عددا من الآفات تمثلت بالتنکس، توسع فسحة بومان، ارتشاح الخلایا الالتهابیة فی النسیج الخلالی واحتقان الشعیرات الدمویة وازدادت هذه الآفات عند الترکیز 6 ملغم/کغم من وزن الجسم. سبب العقار انخفاض فی وزن کل من الفئران الحوامل، الأجنة والأعضاء قید الدراسة وکانت شدة الانخفاض مرتبطة بترکیز الجرعة المعطاة. وأظهرت نتائج الفحوص الکیموحیویة زیادة فی مستوی أنزیمات مصل الدم ناقلة أمین الالنین وناقلة أمین الاسبارتیت والفوسفتاز القاعدی فی المجموعتین الأولى والثانیة، فضلا عن أن الزیادة فی مستوی کل من نیتروجین الیوریا والیوریا فی المجموعتین الأولى والثانیة مقارنة بالمجموعة الأولى وعلى التوالی، بینما الزیادة فی مستوی الکریاتنیین کانت واضحة فی المجموعة الثانیة مقارنة بمجموعة السیطرة وبهذا یمکن القول ببساطة، أن استعمال مضادات السرطان خلال فترة الحمل یمکن أن یسبب تأثیرات ضارة فی جسم کل من الأمهات الحوامل وأجنتها. ویکمن خطر هذه العقاقیر فی کونها تعبر الحاجز المشیمی وتصل إلى الجنین، وتؤثر على عملیة تکوین الاعضاء. یسبب هذا العقار ایضا تحویرا فی نظام عمل مضادات الاکسدة فی جسم الامهات الحوامل خلال فترة العلاج، وبهذا یجب اخذ هذا العقار تحت المتابعة والاشراف الطبی.
Introduction
Platinum is a metallic collaboration compound, belongs to the class of platinum-based antitumour drugs, these drugs are used in the treatment of many types of cancers such as germ cell tumours, ovarian cancer, cervical cancer, testicular cancer (1). Platinum is a water-soluble inorganic divalent agent (2), and classified as an alkylating - like factor. Platinum is given by injection into a vein (IV) or directly into the peritoneal cavity (IP), (3). Cancer is a time disease. The rate of cancer occurrence during gestation is increasing day after day. Treating pregnant women with drugs was considered one of the causes of cancer (4). Chemical treatment was used in cancer therapy during gestation because of its effective results. Furthermore, the safety of using it during this critical period has not sufficiently studied. Platinum is a good choice for treating cancer during gestation, except that the drug can kill rapidly proliferating cells, and the fetus represented just as a rapidly proliferating cell mass (5), as well as the possibility of affecting the maternal organs and impairing fetal development (6). The drug promotes cytotoxicity by forming covalent bonds with nucleophile purine -N7 sites in DNA, it also affects DNA replication, transcription and induces cell death (7), nephrotoxicity, and hepatotoxicity (8), especially if high doses were used (9). The previous data confirmed that the use of anticancer drugs during pregnancy, especially during the first trimester may cause a structural, and a functional disturbance in both mother and fetus bodies (10-12), it also may cause early delivery, intracranial bleeding because the drug can be easily absorbed, and transferred to the fetus through the placenta. The drugs used to treat cancer, although they destroy cancer cells, they cause abnormal changes in the normal cells of the vital organs, especially those responsible for detoxification such as liver and kidney (13). Exposure to the high doses of anticancer gives rise to the rate of oxidative stress in both liver, and kidney of rodents, as well as promotes ovary problems in women (14,15). The drug accumulates in the mitochondria, and induces cellular mitochondrial damage that has a teratogenic effect on the mouse embryonic development (16,17). The current study aimed to investigate the toxic effects of the doses 3and 6 mg/ kg of b.w. of a Platinum drug on the liver, kidneys of both pregnant mice Mus musculus and their fetuses, in addition to the body weight of the mothers, selected organs, and the fetuses. The pregnant mice were injected with certain doses intraperitoneally (IP) on the days 7th, 12th, and 17th of pregnancy as a one single dose per day. Moreover, some biochemical variables were measured in the maternal serum to evaluate the sufficiency of both maternal liver, and kidney functions.
Materials and methods
Animal husbandry
Thirty pregnant mice Mus musculus weighted 29±3 gm at age 60±4 days were used in the current study. The study was conducted within 4 months. Animals were brought from the animal's house of the College of Veterinary Medicine, Mosul University, and Mosul, Iraq. All animals were housed in standard plastic cages with free access to their food and water. They were kept in the animals' house of the department of Biology, College of Education for Pure Science. They exposed to an equal day/night cycle, at 23±3ºC. Animals were treated following the care and the use of laboratory animal guides. For mating, both males and females were caged together for overnight (one male / two female per cage) (18). The presence of a vaginal plug was examined early in the morning, and considered as the first day of pregnancy (19). Selected mice were isolated in separated cages. The drug used in the present study was the Platinum (Cis-diamminedichloroplatinum) injection solution (50 mg /100 ml) produced by Kang Pharmacy, Haryana, India.
Experimental design
Pregnant mice were divided into three groups (each group consisted of 10 pregnant mice), as the following; group I: (control group) was injected intraperitonialy (IP) with 0.2 ml of distilled water at the days 7th, 12th, and 17th of pregnancy for once. Group II: injected (IP) with 3 mg/kg of b.w. of Platinum at the days 7th, 12th, and 17th of pregnancy for once. Group III: injected (IP) with 6mg/kg of b.w. of Platinum at the days 7th, 12th and 17th of pregnancy for once. The doses were withdrawn from the drug solution by insulin syringe (0.1 ml). The volume of the doses was determined to be appropriate for the weight of pregnant mice. The selected doses were chosen depending on the LD50 of the Platinum, which is 7.5mg /kg of b.w. for mice (20).
Specimens preparation and examination
Pregnant mice were euthanized, and dissected on the 17th day of pregnancy. Fetuses, liver, kidney of both mothers and fetuses were isolated, weighed, and washed with distilled water. All specimens were fixed with formalin 10% fixative for 48 hours. After fixation, the specimens were washed with distilled water for 2 hours, and the samples were processed routinely. Sections were stained with Delafield's Hematoxylin and Eosin. The slides were mounted with DPX (21). The histological examination was done using an optical microscope. For photography, a digital camera was used (type MDCE-5A, Japan). The camera was connected to the optical lens of the microscope. Blood samples were collected using a method of the retro-orbital plexus prior to dissection. Collected blood was kept in the anticoagulant tubes. The serum was prepared using the standard method used in the biochemical laboratories.
Biochemical evaluation of maternal liver and kidney functions
The activities of alanine transferase (ALT), alkaline phosphatase (AIP), and aspartate aminotransferase (AST) enzymes were measured using the antioxidant assay kit (Sigma-Aldrich, C50790) to evaluate the efficiency of the maternal liver function. Furthermore, Urea, uric acid, creatinine, and blood urea nitrogen (BUN) were measured using commercial kits (Biomerieux, France) to evaluate the competence of maternal kidney.
Data analysis
The current data including; weight changes in the body of mothers and fetuses, selected organs, and activities of maternal liver and kidney biomarkers were expressed as mean ± standard deviation (SD). The data were statistically analyzed using one -way ANOVA (one -way analysis of variance). Dunnett's test (multiple comparison method) was used to indicate the differences by comparing the means of each experimental groups II, and III with the mean of the control group I. The statistical estimations of the current data were achieved using statistical software Graph Pad Prism 5.0 (San Diego, USA). The significance level was set at *P, **P<0.01; a highly significant, and*** P<0.001; avery highly significant.
Results
Histopathological observations of the maternal and fetal liver
Light microscopic examination of the control liver sections of pregnant mice showed normal liver tissue composed of central vein, and hepatocytes (Figure 1).
Figure 1: Cross-section of pregnant mice Mus musculus liver (control) showing; normal liver tissue composed of the central vein (C), and normal hepatocytes (H). (H&E, 400X)
Liver sections of the mothers' group II showed; vacuolation of hepatocytes, congestion of the central vein (Figure 2). Moreover, apoptosis, and necrosis of some hepatocytes also were observed (Figure 3).
Figure 2: Cross-section of pregnant mice Mus musculus liver injected (IP) with a Platinum drug at the dose of 3 mg/kg of b.w. on the days 7th , 12th ,and 17th of pregnancy showing; vacuolation (V, C) of hepatocytes, and congestion (Con) of the central vein. (H&E, 400 X).
Figure 3: Cross-section of pregnant mice Mus musculus liver injected (IP) with a Platinum drug at the dose of 3 mg/kg of b.w. on the days 7th , 12th , and 17th of pregnancy showing; apoptosis (AP) , and necrosis (N) of some hepatocytes. (H&E, 400 X).
At the dose of 6 mg /kg of b.w. of Platinum, the lesions were increased, and represented with the dilatation of sinusoids, an increase in the eosinophil’s, and vacuolation of hepatocytes (Figure 4). Furthermore, congestion of the portal vein, and infiltration of the inflammatory cells were observed in the portal area (Figure 5).
Figure 4: Cross-section of pregnant mice Mus musculus liver injected (IP) with a Platinum drug at the dose of 6 mg/kg of b.w. at the days 7th , 12th , and 17th of pregnancy showing; dilatation of sinusoids (DS), increase in the eosinophil’s (E) ,and vacuolation (V) of hepatocytes. (H&E, 400X).
Figure 5: Cross-section of pregnant mice Mus musculus liver injected (IP) with a Platinum drug at the dose of 6 mg/kg of b.w. at the days 7th , 12th ,and 17th of pregnancy showing; congestion of the portal vein (Con), Inflammatory cells infiltration (ICI) in the portal area. (H&E, 400X).
The light microscope examination of the fetal liver of the control group I revealed; normal hepatic primitive tissue (Figure 6).
Figure 6: Cross-section of the fetal liver of pregnant mice Mus musculus (control) showing; normal hepatic primitive tissue. (H&E, 400 X).
Fetal liver sections of mothers' group II showed; congestion of the blood capillaries between hepatocytes, presence of extramedullary hematopoietic cells, and mild degeneration of the primitive hepatocytes (Figure 7).
Figure 7: Cross-section of the fetal liver of pregnant mice Mus musculus injected (IP) with a Platinum drug at the dose of 3 mg/kg of b.w. on the days 7th, 12th, and 17th of pregnancy showing; congestion (Con), extramedullary hematopoietic cells (circles), and degeneration (D) of the primitive hepatocytes. (H&E, 400 X).
At the dose of 6 mg/kg of b.w. congestion was increased (Figure 8), and primitive hepatocytes showed severe degeneration (Figure 9).
Figure 8: Cross-section of the fetal liver of pregnant mice Mus musculus injected (IP) with a Platinum drug at the dose of 6mg/kg of b.w. on the days 7th, 12th, and 17th of pregnancy showing; an increase in the congestion (Con). (H&E, 400X).
Figure 9: Cross-section of the fetal liver of pregnant mice Mus musculus injected (IP) with a Platinum drug at the dose of 6mg/kg of b.w. at the days 7th, 12th, and 17th of pregnancy showing; severe degeneration (D) of the primitive hepatocytes. (H&E, 400X)
Histopathological observations of the maternal and fetal kidneys
Light microscope examination of the maternal kidney sections of the control group I showed; normal renal tissue composed of glomerulus, and renal tubules (Figure 10).
Figure 10: Cross-section of pregnant mice Mus musculus kidney (control) showing; normal renal tissue composed of glomerulus (G), and renal tubules (R). (H&E, 400X).
Sections from mothers group II showed; degeneration of proximal convoluted tubules epithelium, and expansion of Bowman’s space (Figure 11).
Figure 11: Cross-section of pregnant mice Mus musculus kidney injected (IP) with a Platinum drug at the dose of 3 mg/kg of b.w. on the days 7th, 12th, and 17th of pregnancy showing; degeneration (D) of proximal convoluted tubules epithelium , and expansion of Bowman’s space (E). (H&E, 400X)
Moreover, kidney sections of mothers' group III showed; an increase in the inflammatory cells infiltration in the interstitial tissue, and severe degeneration of the proximal convoluted tubules epithelium (Figure 12).
Figure 12: Cross-section of pregnant mice Mus musculus kidney injected (IP) with a Platinum drug at the dose of 6 mg/kg of b.w. on the days 7th , 12th , and 17th of pregnancy showing; an increase in the inflammatory cells infiltration in the interstitial tissue (ICI), and degeneration (D) of proximal convoluted tubules epithelium. (H&E, 400X).
Microscopical examination of the fetal kidney of the control group I showed; normal renal primitive tissue composed of primitive renal tubules, and primitive glomerulus (Figure 13).
Figure 13: Cross-section of the fetal kidney of pregnant mice Mus musculus (control) showing; normal renal primitive tissue composed of primitive renal tubules (PT), and primitive glomerulus (PG).(H&E, 400X).
Sections from mothers group II showed; degeneration of the primitive tubules epithelium, and congestion of the blood capillaries within the interstitial tissue (Figure 14).
Figure 14: Cross-section of the fetal kidney of pregnant mice Mus musculus injected ( IP) with a Platinum drug at the 3 mg/kg of b.w. on the days of 7th , 12th , and 17th of pregnancy showing; degeneration (D) of primitive renal tubules epithelium, and congestion (Con) of blood capillaries within the interstitial tissue. (H&E, 400X)
Sections of mothers group III showed; an increase in the degeneration of the primitive renal tubules epithelium, and an increase in the congestion of the blood capillaries within the interstitial tissue (Figure 15).
Figure 15: Cross-section of the fetal kidney of pregnant mice Mus musculus injected ( IP) with a Platinum drug at the 6mg/kg of b.w. on the days of 7th , 12th , and17th of pregnancy showing; an increase in the degeneration (D) of the primitive renal tubules epithelium, and an increase in the congestion (Con) of the blood capillaries in the interstitial cells. (H&E, 400X).
Weight changes
Throughout the experimental period, all groups I, II and III were weighted twice in the days 7th and 17th of pregnancy. Both groups II, and III showed a significant reduction P> 0.05, and a highly reduction P> 0.01 in maternal body weight compared to the control group, respectively. Maternal liver of both groups II, and III did not show any change in their weight compared to the control group I, respectively. Group III showed a significant decrease P> 0.05 in the maternal kidney weight, but group II did not report any weight changes compared to the control group I, respectively. Furthermore, There had been a highly decrease P> 0.01, and a non-significant decrease in the fetal body weight of both groups II, and III compared to control group I, respectively (Table 1).
Table 1: Illustrates the effect of two doses 3 and 6 mg/kg b.w. of Platinum administrated to the pregnant mice at the days 7th, 12th, and 17th of gestation on the maternal weight of the body, liver, kidneys, and the fetal body weight
|
Control |
Group II |
Group III |
Mean Body Weight on the 7th day |
26.54±0.45 |
27.1±1.07 |
27.04±0.21 |
Mean body Weight on the 17th day |
29.91±0.94 |
27.56±1.06* |
26.85±1.17** |
Mean Liver Weight on the 17th day |
2.14±0.21 |
2.09±0.73 |
1.79±0.43 |
Mean Kidney Weight on the 17th day |
1.58±0.29 |
1.48±0.28 |
1.06±0.12* |
Mean foetus Weight on the 17th day |
1.32±0.06 |
1.22±0.16 |
0.96±0.11** |
All values were expressed with mean ± standard deviation (SD), the significance level was estimated at; *P> 0.05; significant, and **P> 0.01; a highly significant. Dunnett's test was employed to determine the differences by examining each mean of groups II, and III with the mean of the control group I.
Effect of Platinum on the maternal liver and kidney functions
The biochemical estimation of the maternal serum of both groups II, and III showed; a highly significant increase P> 0.01, and non-significant changes in the activity of AST compared to the control group I, respectively. ALT levels of both groups III, II showed a very highly significant increase P>0.001, and a highly significant increase P>0.01 compared to the control group I, respectively. ALP activity showed a significant increase P
Figure A: Explaining the impact of two doses 3 and 6 mg /kg b.w of Platinum administrated to the pregnant mice at the days 7th , 12th , and 17th of gestation on the levels of motherly serum enzymes including; AST, ALT, and ALP. The data were expressed as mean ± standard deviation (SD), and n=three. All values were considered significant at *P> 0.05, a highly significant at ** P > 0.01, a very highly significant at *** P > 0.001, and ns- non-significant compared to the control group I. Dunnett's test was employed to show the differences by comparing the mean of each enzyme of both experimental groups II, and III with the mean of control group I.
Biochemical testing of the maternal serum that performed to assess the competence of the kidney functions, clearly demonstrated; a highly significant increase of P > 0.01 in the BUN levels of both groups II, and III compared to control group I, respectively. Both groups II, and III revealed; a highly significant raise P<0.01, and non-significant changes in the levels of creatinine compared to the control group I, respectively. Furthermore, they also revealed; a significant raise P > 0.05, and a highly significant raise P > 0.01 in levels of urea compared to the control group I, respectively (Figure B).
Figure B: Explaining the effect of two doses 3and 6 mg /kg b.w. of a Platinum on the levels of motherly serum BUN, Creatinine, and Urea. The drug was administrated to the pregnant mice at the days 7th, 12th, and 17th of gestation. The results were expressed as mean ± standard deviation (SD), (n=3), ns - non-significant. The values were considered significant at *P> 0.05, and a highly significant at ** P
The current study revealed a significant P>0.05, and a highly significant P>0.01 reduction in the maternal body weight of both groups II and III compared to the control group I, respectively. Maternal kidneys of group III showed; a significant reduction P0.01 in the fetal body weight of group III. The current findings were agreed with those of (46-48), where all authors confirm the effect of the Platinum on the rodent's weight. Moreover, the weight reduction in the maternal bodies, liver, kidneys, and embryos in the current study may due to that Platinum alters lipid metabolism, and induce weight loss in both of the mothers, and fetuses (49). Alternatively, may due to that Platinum increase the markers of lipolysis in the white adipose tissue (WAT), B-oxidation, and suppressed lipogenesis in the liver. Thus, these markers had regulated by other factors in a tissue-specific manner. On the other hand, maybe because of the decrease in the ability to concentrate urine resulting in papillary hypertonicity, that is considered the main reason for losing body weight (49,50).
Biochemically, the maternal serum of group III showed; a highly significant increase P>0.01 in the levels of AST, ALP, and a very highly significant increase P>0.001 in the level of ALT. Thus, the rise in the levels of these enzymes indicates disruption of liver function. Whilst, both groups II and III showed; a highly significant increase P
Conclusions
Compared to the benefits of using anticancer drugs in cancer therapy at high doses, it might cause many adverse effects. Thus, the consequence of the drug depended on the doses, and the exposure period. The recent research established the toxic effect of the Platinum drug over both doses of 3 and 6 mg/kg b.w on pregnant mice administered at certain days of gestation. The medication had injured both mothers fetuses 'liver and kidneys, especially if used during delicate pregnancy stages including; the first trimester, the second trimester, and the third trimester. The selected drug alters the regulation of the antioxidant levels in the living body. Thus, the drug should be taken under special medical care, and the patient must adhere to the certain dose prescribed by the specialist.
Acknowledgment
The authors are very grateful to the University of Mosul, the College of Education for the Pure Science, Department of Biology for their support, which helped to improve the quality of this work.
Conflict of interest
The authors declare that there are no conflicts of interest.
- Injecting pregnant white mice with high doses of the platinum drug in certain periods of gestation caused a toxic effect because the drug can pass the placenta and reach the fetal bloodstream.
- Platinum disturbs the histology, the functions of both liver and kidney that belong to the mothers and embryos of white mice.
- Platinum harmed the maternal liver and kidney blood markers. Moreover, the drug caused a bodyweight reduction of both mothers and embryos of white mice.
- Frezza M, Hindo S, Ping D. Novel metals and metal complexes as platforms for cancer therapy. Cur Pharm Des. 2010;16(16):1813-1825. Doi: 10.2174/138161210791209009
- Ravindra P ,Bhiwgade DA, Kulkarni S ,Rataboli PV ,Dhume , CY. Cisplatin induced histological changes in renal tissue of rat. J Cell Anim Bio. 2010;4(7):108-111. Doi: 10.5897/JCAB.9000003
- Mendez LE, Mueller A, Salom E, Gonzalez- Quintero VH. Paclitaxel, and carboplatin chemotherapy administration during pregnancy for advanced epithelial ovarian cancer.Obstet Gynecol. 2003;102:1200-1202. Doi: 10.1016/s0029-7844(03)00698-7
- Rahmani BR, Moslem AR, Rahmani MR, Askari B. The effect of food intake during labour on maternal outcomes:A randomized controlled trial. Ofogh-e- Danesh. GMUHS J.2009;15:17-23. Doi: 10.4103/ijnmr. IJNMR_213_15
- Aoki K, Kajiura S, Matsumoto Y. Preconceptional natural -killer-cell activity as a predictor of miscarriage. Lancet. 1995;345:1340-1342. Doi: 10.1016/s0140-6736(95)92539-2
- Haricharan S, Jie D, Hein S, Jay PR, Zhijun DU, Michael T, Kimberly H, Susan G, Huang S, Rachel A, Wendy W, Sonali J, Virginia FB, Gutierrez C, Hong Z, Schedin PJ, Osborne K, Tweardy Yl. Mechanism and preclinical prevention of increased breast cancer risk caused by pregnancy. Human Bio Med. 2013;1(9):122-142. Doi: 10.7554/eLife.00996
- Siddik ZH. Cisplatin:mode of the cytotoxic and molecular basis of resistance. Oncogene. 2003;22:7265-7279. Doi: 10.1038/SJ.onc.1206933
- Chibber IS, Naseem I. The ameliorative effect of riboflavin on the cisplatin-induced nephrotoxicity and hepatotoxicity under photo illumination. Food Chem Toxicol. 2010;48(8-9):2052-2058. Doi: 10.1016/j.fct.2010.05.004
- Zecca A, Cafaggi S, Mariggio MA, Vannozzi MO, Ottone NI, Bocchini V, Caviglioli G, Ciale M. Reduction of cisplatin hepatotoxicity by procainamide hydrochloride in rat. Eur J Pharmacol. 2002;44(3):265-272. Doi: 10.1016/s0014-2999(02)01537-6
- Series K, Weqrzynow E, Jassem J. Paclitaxel and cisplatin chemotherapy for ovarian cancer during pregnancy:case report and review of the literature. Arch Gynecol Obstet. 2011;28(1):97-100. Doi: 10.1007/s00404-011-1855-4
- Yong II, Kim KT. Gynaecologic malignancy in pregnancy. Obstet Gynecol Sci. 2013;56(5):289-300. Doi: 10.5468/ogs.2013.56.5.289
- Yoshinaka A, Fukasawa I, Sakamoto T. The fertility and pregnancy outcomes of patients who underwent preservative operation followed by adjuvant chemotherapy for malignant ovarian tumours. Gyne Obst. 2000;264(3):124-127. Doi: 10.1007/s004040000094
- Longo VD, Mattson MP. Fasting:molecular mechanisms and clinical applications. Cell Metab. 2014;19(2):181-192. Doi: 10.1016/j.cmet.2013.12.008
- Naziroglu M, Senol N, Ghazizadeh V, Yuruker V. Neuroprotection induced by N-acetylcysteine and selenium against traumatic brain injury-induced apoptosis and calcium entry in the hippocampus of the rat. Cell Mol Neurobiol. 2014;34,895-903. Doi: 10.1007/s10571-014-0069-2
- Kursunluoglu G ,Kayali HA, Taskiran D. The effect of cisplatin of toxicity and capsaicin on electron transport chain in liver and kidney of Sprague Dawley rats. Cell Biochem Biophys. 2014;69(3):707-716. Doi: 10.1007/s12013-014-9857-z
- Singh SV, Srivastava SK, Choi S, Lew KL, Sulforaphane-induced cell is death in the human prostate cancer cell death is initiated by reactive oxygen species. J Biol Chem. 2005;280:19911. Doi: 10.1074/jbc.M412443200
- Ghaemmaghami F, Hasanzadeh M. The good fetal outcome of pregnancy with Gynecologic cancer condition: Cases and literature review. Int J Gynecol Can. 2006;16(1):1-7. Doi: 10.1111/j.1525-1438.2006.00510.x
- Salah BA. Histopathological effect of fluoxetine drug on the brain of pregnant mice and their embryos. Iraqi J Vet Sci. 2020;34(1):71-76. Doi: 10.33899/ijvs.2019.125467.1006
- Ali MO, El- Nahass E, Diamond MO, Desouki G. Embryo toxic effect diabetes mellitus. Al-Azhar Med J. 1989;17(4):421-228. Doi: 10.12816/0026270
- Aston WJ, Hope ED, Nowak Ak, Robinson BW, Lake RA, lesterhuis WJ.A systematic investigation of the maximum tolerated a dose of cytotoxic supportive care in mice. BMC Cancer. 2017;17:684. Doi: 10.1186/s12885-017-3677-7
- Al-Haaik AG. A gross anatomical and histological study of pancreas in adult Kestrel (Falco tinnunculus). Iraqi J Vet Sci. 2019;33(2):175-180. Doi: 10.33899/ijvs.2019.162960
- Santos NA, Martins NM, Curti C, Pires B ML, Santos AC. Dimethylthiourea protects against mitochondrial oxidative damage induced by cisplatin in the liver of the rat. Chem Biol Interact. 2007;170(3):177-68.
- Mir M, Arab MR, Shahraki MR, Mashhad MA, Salar MS, Aral FS, Karimfar MH. Toxic effects of cisplatin on hepatocytes and liver enzymes of the rat. Anat Sci. 2015;12(4):171-175. Doi: 10.7314/APJCP.2014.15.17.7389
- Soni H, Kaminski, D, Gangaraju R, Adebiyi A. Cisplatin-induced oxidative stress stimulates renal Fas ligand shedding. Ren Fail. 2018;40(1):314-322. Doi: 10.1080/0886022X.2018.1456938
- El-Sayyad HI. Histopathological effects of cisplatin, doxorubicin and 5-flurouracil (5-FU) on the liver of male albino rats. Int J Biol Sci. 2009;5(5):466-473. Doi: 10.7150/ijbs.5.466
- Lu Y, Cederbaum.Cisplatin-induced hepatotoxicity is enhanced by elevated expression of cytochrome P450 2E1. Toxi Sci. 2005;89(2):515-523. Doi: 10.1093/toxsci/kfj031
- Kamble PR, Bhiwgade D. Cisplatin-induced histological and ultrastructural alternation in liver tissue of rat. J Cytol Hist. 2011;2:128. Doi: 10.4172/2157-7099.1000128
- Ezz-Din D, Garbry A, Farrage ARH, Abdel Moneim E. Physiological and histological impact of Azadirachta indica (neem) leaves extract in a rat model of cisplatin-induced hepatic and nephrotoxicity. J Med plant. 2011;5(23):5499-5506. Doi: 10.5897/JMPR.9000980
- Palipoch SC, Punsawad P, Koomhin P, Suwannalert P. Hepatoprotective effect of curcumin and alpha-tocopherol against cisplatin-induced oxidative stress. BMC Com Med. 2014;14(1):111. Doi: 10.1186/1472-6882-14-111
- Gerschenson M, Paik CY, Gaukler E, Diwan BA, Poirier MC. Cisplatin exposure induces mitochondrial toxicity in pregnant rats and their fetuses. Rep Toxi. 2001;15(5):525-531. Doi: 10.1016/s0890-6238(01)00156-3
- Ognio J, Chiavarina B. Study of the feasibility of the treatment with procainamide hydrochloride and cisplatin in pregnant mice.Chemico-Biological Inte. 2007;164(3):232-40. Doi: 10.1016/j.cbi.2006.10.001
- Keller KA, Aggarwal SK. Embryotoxicity of cisplatin in rats and mice. Toxicol Apple Pharmacol. 1983;30(2):245-256. Doi: 10.1016/0041-008x(83)90305-8
- Kohler C, Oppelt P, Favero G. How much platinum passes the placental barrier? Analysis of cervical cancer during pregnancy. Amer J Obst Gyn. 2015;213(2):206-206. Doi: 10.1016/j.ajog.2015.02.022
- Yeh J, Kim BS, Persie J. Reproductive toxic effect of cisplatin and its modulation by the antioxidant sodium 2-Mercaptoethanesulfonate (Mesna) in female rats. Rep Bio Insi. 2011;5:17-27. Doi: 10.4137/RBI.S7663
- Amant F, loibl S, Neven P, Van Calsteren K. Brest cancer in pregnancy. Lancet. 2012;370:570-579.
- Yuen P M, Ng PS, Leung Pl, Rogers MS. The outcome in Laparoscopic management of persistent adnexal mass during the second trimester of pregnancy. Surg Endosc. 2004;18:1354-1357. Doi: 10.1007/s00464-003-8283-x
- Haler ZV, Perse M. Cisplatin-induced rodent model of kidney injury:characteristics and challenges. Bio Med Res Inter. 2018;20(18):29. Doi: 10.1155/2018/1462802
- Ozkok A, Edelstein CL. Pathology of cisplatin-induced acute kidney injury. Biomed Res Int. 2014;2014:967826. Doi: 10.1155/2018/1462802
- Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanism of cisplatin nephrotoxicity. Toxins. 2010;2:2490-2518. Doi: 10.3390/toxins2112490
- Hultstrom M, Becirovic M, Jonsson S. Comparison of acute kidney injury of different aetiology reveals an in-common mechanism of tissue damage. Physiol Genomics. 2018;50(1):127-141. Doi: 10.1152/physiolgenomics.00037
- Giuseppa M, Giuseppe C, Anna C, Michele P, Silvia C, Giuseppina C, Leonardo DM, Mario M. Cisplatin-induced kidney injury in the rat:l-carnitine modulates the relationship between MMP-9 and TIMP-3. Expt Toxicol Pathol. 2009;6:183-188. Doi: 10.1016/j.etp.2008.07.004
- Lajer H,Kristensen M, Hansen HH. Magnesium depletion enhances cisplatin nephrotoxicity. Can Chemother Pharmacol. 2005;56(5):535-542. Doi: 10.1007/s00280-005-1010-7
- Townsend DM, Tew KD, HeL, King JB, Hanigan MH. Role of glutathione S-Transferase Pi in cisplatin-induced nephrotoxicity. Biomed Pharmacother. 2009;63:79-85. Doi: 10.1016/j.biopha.2008.08.004
- Zazuli Z, Vijverberg S, Maitland-van der zee A. Genetic variation and cisplatin nephrotoxicity: A systematic review. Front Pharmacol. 2018;9:1111. Doi: 10.3389/fphar.2018.01111
- Eshkoli T, Sheiner E, Ben-Zvi Z, Holcberg G. Drug transport across the placenta. Curr Pharm Biotech. 2011;12(5):707-714. Doi: 10.2174/138920111795470877
- Guindon J, Deng L, Baochang F, Wager J. Optimization of cisplatin model of chemotherapy-induced peripheral neuropathy in mice, which use of vitamin C and sodium bicarbonate to pretreatments to reduce nephrotoxicity and improve animal health status. Molecular Pain. 2014;10(1):56. Doi: 10.1186/1744-8069-10-56
- Soni KK, Kim Hk, Choi BR, Karma KK, You JH, Cha JS, Shin YS, Lee SW, Kim CY, Park JK. Dose-dependent effects of cisplatin on the severity of testicular injury in Sprague Dawley rats:reactive oxygen species and endoplasmic reticulum stress. J Drug Design Deve Thera. 2016;2016(10):3959-3968. Doi: 10.2147/DDDT.S120014
- Nasiri M, Sottani N, Mazahen S., Maleki M, Talebi A, Gharibi F, Nematbakhsh M. The role of gamma aminobutyric acid in cisplatin-induced nephrotoxicity in streptozotocin-induced diabetic rats. Adv Biomed Res. 2017;6:96. Doi: 10.4103/2277-9175.211834
- Garcia JM, Scherer T, Chen Ji-an, Guillory B, Nassif A, Popusha V, Smiechowska J, Asnicar M, Buettner C and Smith R G. Inhibition of cisplatin -Induced lipid catabolism and weight loss by Ghrelin in male mice. End Soci. 2013;22(3):99-101. Doi: 10.1210/en.2013-1179
- Seaman F, Sawhney P, Giammona CJ, Richburg JH. Cisplatin-induced plus of germ cell apoptosis precedes long-term elevated. Apoptosis. 2003;8(1):101. DoiI: 10.1023/a:1021734604913
- Longchar A, Prasad SB. Biochemical changes associated with ascorbic acid-cisplatin combination therapeutic efficacy and protective effect on cisplatin-induced toxicity in tumor-bearing mice. Toxicol Rep. 2015;7(2):489-503. Doi: 10.1016/j.toxrep.2015.01.017
- Chengwei NI, Man MI, Xiao HI, Zimin WV, Hangyan LV. Hyperin protects against cisplatin-induced liver injury in mice. Acta Cir Bras. 2017;32(8):633-640. Doi: 10.1590/s0102-865020170080000005
- Ateşşahin A1, Karahan I, Türk G, Gür S, Yilmaz S, Ceribaşi AO. Protective role of lycopene on cisplatin-induced changes in sperm characteristics, testicular damage, and oxidative stress in rats. Reprod Toxicol. 2006;21(1):42-7. Doi: 10.1016/j.reprotox.2005.05.003
- Article View: 804
- PDF Download: 495